The Innovation at a Glance
US11534498B2, titled Polyglutamated antifolates and uses thereof, discloses advanced drug formulations involving polyglutamated antifolates encapsulated in liposomes. This innovation addresses treatment of hyperproliferative disorders such as cancer and immune-related conditions including rheumatoid arthritis. By combining novel synthesis methods and liposomal delivery systems, the patent optimizes bioavailability and therapeutic targeting, potentially improving efficacy and safety profiles.
The Inventor & Company Behind It
The patent is assigned to LEAF Holdings Group LLC, a player within the HEALTHTECH domain focused on pharmaceutical innovation. The company’s expertise is reflected in their ability to develop sophisticated biochemical formulations. This patent showcases LEAF Holdings Group’s commitment to advancing next-generation therapies through novel drug delivery platforms and chemical modification techniques.
Market Opportunity
The therapeutic areas targeted by this patent - oncology and autoimmune diseases - represent substantial and growing markets characterized by high unmet medical needs. By providing a distinct mechanism for drug delivery and enhanced treatment modalities, the technology could play a critical role in expanding treatment options for patients. Should clinical and regulatory milestones be achieved, these polyglutamated antifolate formulations may unlock significant commercial potential within these competitive yet lucrative sectors.
Growth Indicators
The patent’s citation count stands at 678, indicating strong recognition and influence within the scientific and intellectual property communities. Additionally, a HIS score of 84.0 underscores the patent's high technological significance and potential impact. These metrics suggest that the underlying technology is both robust and relevant, signaling maturation toward commercialization and strategic deployments such as licensing or partnerships.
Why IP Investors Are Watching
Investors surveying the HEALTHTECH landscape will note this patent’s compelling combination of advanced biochemical engineering and practical therapeutic application. The intersection of innovative polyglutamated antifolates with liposome drug delivery systems enhances its defensive position and attractiveness in an IP-dense market. Although clinical validation and regulatory approval remain prerequisites, the patent’s development stage and strong portfolio profile make it an important asset for investors focused on long-term value creation in pharmaceutical innovation.
Get the Full Analysis
To explore how this patent fits into broader trends in tumor and autoimmune treatment innovation, and assess its positioning within LEAF Holdings Group LLC’s portfolio, access the comprehensive report on IPI Terminal. Our detailed patent intelligence and market insight equip investors to make informed decisions on opportunities in HEALTHTECH innovation.